The combined therapy of intervention, operation and biology in patients with middle-advanced renal cell carcinoma.
- Author:
Xi-shuang SONG
1
;
Zhong-zhou HE
;
Ji-bin YIN
;
Ren-ke ZHANG
;
Xiang-yu CHE
;
Jian-bo WANG
Author Information
- Publication Type:Journal Article
- MeSH: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; therapeutic use; Cancer Vaccines; therapeutic use; Carcinoma, Renal Cell; pathology; therapy; Combined Modality Therapy; Embolization, Therapeutic; Female; Follow-Up Studies; Humans; Kidney Neoplasms; pathology; therapy; Male; Middle Aged; Neoplasm Staging; Survival Rate
- From: Chinese Journal of Surgery 2004;42(23):1450-1452
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo observe the effect of the combined therapy of intervention, operation and biology in patients with middle-advanced renal cell carcinoma.
METHODSCombined therapy was used in 52 cases as combined care groups and the single operational therapy was used in 50 cases as control group. Compare their resection rates, surgical risks and 3, 5 years survival rates.
RESULTSIn the combined care group, the excision rate was 100%, the average amount of blood transfusion during the operation was 280 ml, the average operation time was 100 minutes, and the 3, 5 years survival rates were 73% and 50%; While in the control group, the results were 90%, 396 ml, 130 minutes, 55% and 27% respectively. There were significant differences between 2 groups (P < 0.05).
CONCLUSIONCombined therapy could elevate resection rates and 3, 5 years survival rates and decrease surgical risks.
